Navigation Links
First Clinical Volumetric Modulated Arc Therapy Treatment Completed With Elekta Synergy(R) S at General Hospital Vienna
Date:2/13/2008

ATLANTA, Feb. 13 /PRNewswire/ -- On Thursday, January 31, General Hospital Vienna successfully completed its first Volumetric Modulated Arc Therapy (VMAT)* treatment. The hospital is one of the first in the world to carry out this innovative cancer treatment option.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020318/ELEKTALOGO )

VMAT technology provides a simultaneous control of the linear accelerator gantry position and speed, the leaves and angle of the multileaf collimator and dose rate. This flexibility enables highly conformal cancer treatments, as well as optimal sparing of the healthy tissue around the target. In addition, VMAT significantly reduces patient treatment times, leading to greater patient comfort and stillness for a more efficient and precise treatment.

Dietmar Georg, Ph.D., head of the Division of Medical Radiation Physics at General Hospital Vienna (Medical University Vienna, Vienna, Austria) says the first patient was treated for glioblastoma, a serious brain tumor that was positioned near vital structures such as the brain stem and optical lenses and nerves. The treatment consisted of three non-coplanar VMAT arcs with collimator rotation. The entire treatment took just 10 minutes, including creation and evaluation of the patient's brain images and treatment positioning.

"This therapy is applied in very complex situations where the localization and form of the tumor requires tailored intensity modulated treatment," says Dr. Georg.

Elekta provides complete VMAT package

General Hospital Vienna used its existing Elekta Synergy(R) S system to perform the VMAT treatment, along with Elekta's next generation linear accelerator control software. Elekta's VMAT solution also includes ERGO++ treatment planning system for rotational therapy, and MOSAIQ(TM) image-enabled oncology Electronic Medical Records (EMR) system. This
'/>"/>

SOURCE Elekta, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015  ResMed Inc. (NYSE: RMD ) today announced ... the quarter was $423.0 million, a 10 percent increase compared ... increase on a constant currency basis). Net income was $91.2 ... ended December 31, 2013. Diluted earnings per share for the ...
(Date:1/22/2015)... SAN DIEGO , Jan. 22, 2015  Profil Institute ... focused on diabetes and obesity, announced today a new ... Drug Development,  published by Springer, a leading global scientific ... extensively analyze and illustrate techniques for use in early ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/w25xpc/allergy ) has announced the ... Product & by End User - Global Forecast to 2019" ... allergy diagnostics market is valued at $1,228.58 million in 2014 ... to reach $2,230.72 million by 2019. Allergy diagnostics is used ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3
... Cellular Dynamics International (CDI) today announced the online ... demonstrating for the first time a methodology for ... banked blood samples through the creation of induced pluripotent ... lymphoblastoid B-cell lines reprogrammed to EBV-free induced pluripotent stem ...
... 2011 Reportlinker.com announces that a new ... catalogue: Product Profiles: Multiple ... market entrants http://www.reportlinker.com/p0564421/Product-Profiles-Multiple-Sclerosis---Gilenya-raises-bar-for-new-market-entrants.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... Beginning with the recent approval ...
Cached Medicine Technology:Cellular Dynamics International Unlocks the Potential of Banked Blood Samples 2Reportlinker Adds Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants 2Reportlinker Adds Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants 3Reportlinker Adds Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants 4Reportlinker Adds Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants 5
(Date:1/22/2015)... Calif. (PRWEB) January 22, 2015 ... Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were ... their leadership in advancing biotechnology, biomedical science, medical ... and Olsen each received the “2014 Life Sciences ...
(Date:1/22/2015)... years since the release of their debut recording Love is King, ... & Matthew Love – the duo are pleased to announce their ... Swan Records on February 24, 2015. , THE ROAD offers the ... all of us to walk out of the mire of our ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 As ... of overall health care gains momentum worldwide, Rev. Eric ... HealthCare Chaplaincy Network (HCCN), will be the keynote ... spiritual care in Israel’s public health system. , The conference, ...
(Date:1/22/2015)... Lower-Auto-Insurance.com has released a new blog post explaining the importance of ... the costs of an auto insurance policy . , Clients ... prices for their vehicle insurance policies. The safety a vehicle offers ... Because of this, drivers should always carry a first aid ...
(Date:12/26/2014)... TX (PRWEB) December 26, 2014 The US ... in this report. In 2013, GlobalData’s forecast estimates that sales ... largest CRC market due to the high incidence of the ... with the 5EU, Japan, and China. Increased sales of CRC ...
Breaking Medicine News(10 mins):Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... can reduce hot flashes effectively. The good news is that cool ... , ... Ann Arbor, MI (PRWEB) July 21, 2008 -- The hot ... debating merits of synthetic or bio-identical hormones. Too much complicated information overwhelms ...
... New data from a study of patients with treatment-resistant ... subcallosal cingulate region (SCG or Cg25) of the brain ... significant improvement in patients as early as one month ... improvement over time. , The data are ...
... Eileen T. Kennedy DSc, Dean of Tufts University,s Gerald ... and Policy announced the 3rd Annual Friedman School Symposium, ... issues facing industry, policy-makers, academics and thought leaders in ... Boston, September 24th to 26th, 2008. , Fifteen experts ...
... iCAD, Inc. (Nasdaq:,ICAD), an industry-leading provider of ... its previously announced,agreement to purchase the principal assets ... in White Plains, NY. The,purchase price was $5 ... shares of iCAD common stock. The number of ...
... leucoanthocyanidins and anthocyanidins are natural, ... antioxidant properties, IRVINE, Calif., July 21 ... phytochemical reference standards and,contract research, announced today its ... agreement with The Research Foundation of the,State University ...
... PITTSBURGH, July 21 Mylan Inc. (NYSE: ... Crookshank as vice president -,Investor Relations and as ... to Chief Financial Officer Edward J. Borkowski, Crookshank ... as for the,development and direction of activities that ...
Cached Medicine News:Health News:Menopause: Hot Flashes Can Be Reduced 90% without Hormones 2Health News:Menopause: Hot Flashes Can Be Reduced 90% without Hormones 3Health News:Promising results in deep brain stimulation for patients with treatment-resistant depression 2Health News:Promising results in deep brain stimulation for patients with treatment-resistant depression 3Health News:'Nutrition Agenda 2008' is focus of Tufts Friedman School Symposium 2Health News:'Nutrition Agenda 2008' is focus of Tufts Friedman School Symposium 3Health News:iCAD Completes Acquisition of CAD Sciences 2Health News:ChromaDex Licenses Green Chemistry Technology to Manufacture a New Class of Super Fruit Compounds 2Health News:ChromaDex Licenses Green Chemistry Technology to Manufacture a New Class of Super Fruit Compounds 3Health News:Daniel E. Crookshank Joins Mylan as Vice President - Investor Relations 2
Ultra-Slip™ endotracheal tube guide for single-patient use only., ,Caution: Not MRI Compatible....
FlexiSlip™ Plastic coated malleable metal core. Single use, Sterile, Latex Free. Soft distal tip flexes to reduce risk of trauma to patient. Malleable metal core is easy to shape. Low friction ...
Endotracheal Tube Stylet- Adult, Copper, Malleable, Non-Sterile, Latex Free, Suitable for tubes 5.0 mm I.D. or larger....
... Requires minimal cervical spine manipulation. Prevent dental ... nasally. Cost effective alternative to X-ray. Light-guided ... the soft tissues in the neck. This ... of the trachea relative to the esophagus. ...
Medicine Products: